Oral 5-ASA Therapy in Ulcerative Colitis : What are the Implications of the New Formulations?SANDBORN, William J.Journal of clinical gastroenterology. 2008, Vol 42, Num 4, pp 338-344, issn 0192-0790, 7 p.Article

Gastroenterology 2 Inflammatory bowel disease : clinical aspects and established and evolving therapiesBAUMGART, Daniel C; SANDBORN, William J.Lancet (British edition). 2007, Vol 369, Num 9573, pp 1641-1657, issn 0140-6736, 17 p.Article

Infliximab in the treatment of Crohn's disease: A user's guide for cliniciansSANDBORN, William J; HANAUER, Stephen B.The American journal of gastroenterology. 2002, Vol 97, Num 12, pp 2962-2972, issn 0002-9270, 11 p.Article

Crohn's diseaseBAUMGART, Daniel C; SANDBORN, William J.Lancet (British edition). 2012, Vol 380, Num 9853, pp 1590-1605, issn 0140-6736, 16 p.Article

Novel approaches to treating inflammatory bowel disease: Targeting alpha-4 integrinSANDBORN, William J; YEDNOCK, Ted A.The American journal of gastroenterology. 2003, Vol 98, Num 11, pp 2372-2382, issn 0002-9270, 11 p.Article

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewBILLIOUD, Vincent; SANDBORN, William J; PEYRIN-BIROULET, Laurent et al.The American journal of gastroenterology. 2011, Vol 106, Num 4, pp 674-684, issn 0002-9270, 11 p.Article

Evidence-based treatment algorithm for mild to moderate Crohn's diseaseSANDBORN, William J.The American journal of gastroenterology. 2003, Vol 98, Num 12, pp S1-S5, issn 0002-9270, SUPArticle

Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel diseaseLOFTUS, Conor G; EGAN, Laurence J; SANDBORN, William J et al.Gastroenterology clinics of North America. 2004, Vol 33, Num 2, issn 0889-8553, vii, 141-169 [30 p.]Article

Diagnosis and treatment of perianal fistulas in Crohn diseaseSCHWARTZ, David A; PEMBERTON, John H; SANDBORN, William J et al.Annals of internal medicine. 2001, Vol 135, Num 10, pp 906-918, issn 0003-4819Article

Biologic therapy of inflammatory bowel diseaseSANDBORN, William J; TARGAN, Stephan R.Gastroenterology (New York, NY. 1943). 2002, Vol 122, Num 6, pp 1592-1608, issn 0016-5085Article

An Update on the Epidemiology of Inflammatory Bowel Disease in AsiaTHIA, Kelvin T; LOFTUS, Edward V; SANDBORN, William J et al.The American journal of gastroenterology. 2008, Vol 103, Num 12, pp 3167-3182, issn 0002-9270, 16 p.Article

AGA technical review on perianal Crohn's diseaseSANDBORN, William J; FAZIO, Victor W; FEAGAN, Brian G et al.Gastroenterology (New York, NY. 1943). 2003, Vol 125, Num 5, pp 1508-1530, issn 0016-5085, 23 p.Article

Once-Daily MMX^® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative ColitisD'HAENS, Geert; SANDBORN, William J; BARRETT, Karen et al.The American journal of gastroenterology. 2012, Vol 107, Num 7, pp 1064-1077, issn 0002-9270, 14 p.Article

Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-AnalysisFORD, Alexander C; KHAN, Khurram J; SANDBORN, William J et al.The American journal of gastroenterology. 2011, Vol 106, Num 12, pp 2070-2077, issn 0002-9270, 8 p.Article

The Natural History of Adult Crohn's Disease in Population-Based CohortsPEYRIN-BIROULET, Laurent; LOFTUS, Edward V; COLOMBEL, Jean-Frederic et al.The American journal of gastroenterology. 2010, Vol 105, Num 2, pp 289-297, issn 0002-9270, 9 p.Article

Crohn's disease : beyond antagonists of tumour necrosis factorPEYRIN-BIROULET, Laurent; DESREUMAUX, Pierre; SANDBORN, William J et al.Lancet (British edition). 2008, Vol 372, Num 9632, pp 67-81, issn 0140-6736, 15 p.Article

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing ParadigmsORDAS, Ingrid; MOULD, Diane R; FEAGAN, Brian G et al.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 4, pp 635-646, issn 0009-9236, 12 p.Article

Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practiceSANDS, Bruce E; KILGORE, Karl M; BLOOMFELD, Richard S et al.Journal of clinical gastroenterology. 2006, Vol 40, Num 7, pp 587-591, issn 0192-0790, 5 p.Article

Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurinePARDI, Darrell S; LOFTUS, Edward V; TREMAINE, William J et al.Gastroenterology (New York, NY. 1943). 2001, Vol 120, Num 6, pp 1483-1484, issn 0016-5085Article

Mid pouch strictureplasty for Crohn's disease after ileal pouch-anal anastomosis: An alternative to pouch excisionMATZKE, Gregory M; KANG, Ajaipal S; DOZOIS, Eric J et al.Diseases of the colon & rectum. 2004, Vol 47, Num 5, pp 782-786, issn 0012-3706, 5 p.Conference Paper

Microscopic colitis: A reviewPARDI, Darrell S; SMYRK, Thomas C; TREMAINE, William J et al.The American journal of gastroenterology. 2002, Vol 97, Num 4, pp 794-802, issn 0002-9270Article

Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patientsRICART, Elena; PANACCIONE, Remo; LOFTUS, Edward V et al.The American journal of gastroenterology. 2001, Vol 96, Num 3, pp 722-729, issn 0002-9270Article

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: Pregnancy and PediatricsMAHADEVAN, Uma; CUCCHIARA, Salvatore; HYAMS, Jeffrey S et al.The American journal of gastroenterology. 2011, Vol 106, Num 2, pp 214-223, issn 0002-9270, 10 p.Article

Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's DiseaseTHIA, Kelvin T; SANDBORN, William J; LEWIS, James D et al.The American journal of gastroenterology. 2008, Vol 103, Num 12, pp 3123-3131, issn 0002-9270, 9 p.Article

Certolizumab pegol for the treatment of crohn's diseaseSANDBORN, William J; FEAGAN, Brian G; STOINOV, Simeon et al.The New England journal of medicine. 2007, Vol 357, Num 3, pp 228-238, issn 0028-4793, 11 p.Article